Bristol-Myers Squibb and Sanofi-Aventis score high in social responsibility rating

15 December 2009

The Roberts Environmental Center (REC) at Claremont McKenna College in the USA has released an analysis of social responsibility reporting for the 26 largest pharmaceutical companies worldwide. The report contains a compilation of Pacific Sustainability Index (PSI) scores evaluating the environmental and social reporting of the companies. Scoring is based on the transparency, intent, and performance for both environmental and social issues.

The research, based entirely on material released on the firms' web sites, found Bristol-Myers Squibb (USA) and Sanofi-Aventis (France) led the sector as the two highest scoring companies. The lowest scoring companies, Forest Laboratories and NBTY, were smaller companies in the sector and are both based in the USA. There was a slight trend between PSI scores and annual revenue; however, Johnson & Johnson and Pfizer, the two largest corporations in the sector, both showed room for improvement.

Prior to the report's release, companies were given the opportunity to respond to their scores and provide additional information if available. Often this reveals information not previously captured in the scoring system.

"Biogen Idec scored low in the rankings," said Elgeritte Adidjaja, research fellow at REC, adding: "However, after speaking with a representative responsible for sustainability matters, the company appears to be committed to many environmental programs, but they are not yet ready to make sustainability information public."

To create the report's ranking, REC evaluated each company's web site using the PSI and sector-specific questions. The index uses a systematic questionnaire to analyze the quality of sustainability reporting. The selection of questions was based on the most frequently-mentioned topics in almost 1,800 corporate sustainability documents analyzed from 2002 through 2008 by the REC. The company's grades in this report were assigned on a grading curve, giving an A+ to the highest scoring companies and those with scores near it.

To view the report, visit: http://www.roberts.cmc.edu/PSI/SectorReports.asp.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical